## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: RMES-02

Group Art Unit: 1645

Examiner: Unassigned

350

Application of:

Christian Siebel et al.

Serial No.:

09/954,483

Filed:

September 17, 2001

For:

Methods of Producing Cells and Animals Comprising Targeted Gene Modifications and Compositions

Relating Thereto

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed April 3, 2002 regarding the above-captioned application, Applicants submit herewith:

- 1. A sequence listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e); and
- 2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The content of the paper and computer readable copies of the sequence listing submitted in this application are the same. Moreover, as the sequence listing merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, no new matter has been introduced into the application.

Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the sequence listing into the application.

Date: June 3, 2002

Respectfully submitted,

Mariette A. Lapiz, Reg. No. 44,202 C

Deltagen, Inc. 740 Bay Road Redwood City, CA 94063 (650) 569-5100

		1		
CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)  Applicant(s): SIEBEL et al.			Docket No.  RMES-02	
Filing Date September 17, 2001	<b>Examiner</b> Unassigned		Group Art Unit	
CING CELLS AND ANIMALS ATING THERETO	COMPRISING TARGETED	GENE 1	MODIFICATIONS AND	
Response to Notice to Containing Nucleotide	Sequence and/or Amin	o Aci	for Patent Applicatio d Sequence Disclosure	
the United States Postal Sen			ope addressed to: The	
s and Trademarks, Washingto	JII, D.O. 20231-0001 5W	June	(Date)	
	(Typed or Printed Name of Pers	<u>\</u>	<b>.</b>	
Note: Each paper must h				
	Filing Date September 17, 2001  CING CELLS AND ANIMALS ATING THERETO  Response to Notice to Containing Nucleotide the United States Postal Sers and Trademarks, Washington	Filing Date September 17, 2001  CING CELLS AND ANIMALS COMPRISING TARGETED  Response to Notice to Comply with Requirem Containing Nucleotide Sequence and/or Amin  (Identify type of correspondence) the United States Postal Service as first class mail in at a s and Trademarks, Washington, D.C. 20231-0001 on  Deborah A. Mojarro  (Typed or Printed Name of Person Mail (Signature of Pe	Filing Date September 17, 2001  CING CELLS AND ANIMALS COMPRISING TARGETED GENE MATING THERETO  Response to Notice to Comply with Requirements of Containing Nucleotide Sequence and/or Amino Acid (Identify type of correspondence)  the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as first class mail in an envelopment of the United States Postal Service as firs	



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D. C. 2023

Www.uspto.dov

VHON NUMBER

FILING RECEIPT DATE

FIRST NAMED APPLICANT

ATTÖRNEY DOCKET NUMBER

09 954,483

09 17 2001

Christian Siebel

RMES-02

TAGEN, INC. Bay Road Redwood City, CA 94063 **CONFIRMATION NO. 6505** 

**FORMALITIES LETTER** 

OC000000007770122\*

Date Mailed: 04/03/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1 821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Heip, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE